γ-(dimethylamino)propyl methanesulfonate | 96363-80-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: γ-(dimethylamino)propyl methanesulfonate
• 英文别名: 3-(dimethylamino)propyl methanesulfonate；methanesulfonic acid-(3-dimethylamino-propyl ester)；Methansulfonsaeure-(3-dimethylamino-propylester)；1-Dimethylamino-3-methansulfonyloxy-propan；Methanesulfonic acid 3-dimethylaminopropyl ester
• CAS: 96363-80-3
• 化学式: C₆H₁₅NO₃S
• 分子量: 181.256
• InChiKey: DMUAMSFZSOIBAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  γ-(dimethylamino)propyl methanesulfonate 在 palladium on activated charcoal 氢气 、 potassium hydride 作用下， 以 乙醇 、 氯仿 为溶剂， 25.0~50.0 ℃ 、137.9 kPa 条件下， 反应 12.5h， 生成 1-O-octadecyl-2-O-acetyl-3-O-[γ-(dimethylamino)propyl]glycerol hydrochloride
  参考文献：
  名称：

  Structure-activity relationship in PAF-acether. 2. RAC-1-O-octadecyl-2-O-acetyl-3-O-[.gamma.-(dimethylamino)propyl]glycerol

  摘要：

  Two products without phosphoryl groups, 1-O-octadecyl-2-O-acetyl-3-O-[gamma-(dimethylamino)propyl]glycerol and its quaternary salt, were synthesized from 1-O-octadecyl-2-O-benzylglycerol. In comparison with PAF-acether, they lost aggregating and bronchoconstrictive activities and did not show any antagonistic effects.

  DOI：

  10.1021/jm00146a019
• 作为产物：
  描述：

  3-二甲氨基-1-丙醇 、 甲基磺酰氯 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 γ-(dimethylamino)propyl methanesulfonate
  参考文献：
  名称：

  [EN] IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER
  [FR] COMPOSÉS IMIDAZO[4,5-C]QUINOLÉINE-2-ONE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER

  摘要：

  该规范通常涉及式(I)的化合物及其药用盐，其中x，R1，R2，R3，R4和R5具有本规范中定义的任何含义。该规范还涉及使用式(I)的化合物及其盐来治疗或预防ATM介导的疾病，包括癌症。该规范进一步涉及包含取代咪唑并[4,5-c]喹啉-2-酮化合物及其药用盐的药物组合物；包含这些化合物和盐的试剂盒；制造这些化合物和盐的方法；以及在这种制造中有用的中间体。

  公开号：

  WO2017076895A1

文献信息

• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS
  申请人：KHAMRAI Uttam

  公开号：US20100168080A1

  公开（公告）日：2010-07-01

  The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

  本发明涉及作为CC趋化因子受体，如CCR1的配体的新型吗啉、恶唑烷和哌啶衍生物。该发明还涉及制备这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。
• [EN] IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER<br/>[FR] COMPOSÉS IMIDAZO[4,5-C]QUINOLÉINE-2-ONE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2017076895A1

  公开（公告）日：2017-05-11

  The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

  该规范通常涉及式(I)的化合物及其药用盐，其中x，R1，R2，R3，R4和R5具有本规范中定义的任何含义。该规范还涉及使用式(I)的化合物及其盐来治疗或预防ATM介导的疾病，包括癌症。该规范进一步涉及包含取代咪唑并[4,5-c]喹啉-2-酮化合物及其药用盐的药物组合物；包含这些化合物和盐的试剂盒；制造这些化合物和盐的方法；以及在这种制造中有用的中间体。
• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20050020684A1

  公开（公告）日：2005-01-27

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W, R 2 is (CH 2 ) n —CH(OR 2 )—(CH 2 ) n E, —(CH)═C(OR 2 )—(CH 2 ) n E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or (CH)═C(Y)(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C o - 4 -alkyl; R 2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or C(S)NR 5 R 6 , R 3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O—, CH 2 —, CH 2 CH 2 — or CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  本发明公开了一种由结构式（I）表示的化合物：其中Ar是取代或未取代的芳香基团。Q是共价键，-CH2-或-CH2CH2-; W是取代或未取代的烷基或取代或未取代的异烷基连接基，长度为两到十个原子，优选长度为两到七个原子。苯环A可选地与R1和W以外的最多四个取代基取代，R2是（CH2）n-CH（OR2）-（CH2）nE，-（CH）=C（OR2）-（CH2）nE，-（CH2）n-CH（Y）-（CH2）mE或（CH）=C（Y）（CH2）mE;其中E是COOR3，C1-C3烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，磺酰胺，酰基磺酰胺和四唑可选地与一个或多个取代基取代，独立地选自：C1-C6烷基，卤代烷基和芳基-Co-4-烷基; R2是H，脂肪基，取代脂肪基，卤代烷基，芳基，取代芳基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或C（S）NR5R6，R3是H，脂肪基，取代脂肪基，芳基或取代芳基。Y是O-，CH2-，CH2CH2-或CH═CH-，并与Phenyl环A中与R1相邻的碳原子键合。R4-R6独立地是H，脂肪基，取代脂肪基，芳基或取代芳基。n和m独立地为0、1或2。
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2019133770A3

  公开（公告）日：2019-08-15